Tvardi Therapeutics (TVRD) announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis. The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls
- Tvardi Therapeutics initiated with an Outperform at Oppenheimer
- Promising Developments and Strong Financial Position Drive Buy Rating for Tvardi Therapeutics
- Tvardi Therapeutics initiated with a Buy at BTIG
- Tvardi Therapeutics Reports Q1 2025 Financial Results